Compare SLDP & RCKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SLDP | RCKT |
|---|---|---|
| Founded | 2011 | 1999 |
| Country | United States | United States |
| Employees | 230 | 202 |
| Industry | Electrical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 662.3M | 534.2M |
| IPO Year | N/A | N/A |
| Metric | SLDP | RCKT |
|---|---|---|
| Price | $3.12 | $3.78 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 14 |
| Target Price | $7.00 | ★ $29.73 |
| AVG Volume (30 Days) | 3.2M | ★ 4.2M |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $48.90 | $69.83 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.04 | $2.19 |
| 52 Week High | $8.86 | $8.26 |
| Indicator | SLDP | RCKT |
|---|---|---|
| Relative Strength Index (RSI) | 49.14 | 46.58 |
| Support Level | $2.94 | $2.99 |
| Resistance Level | $3.22 | $4.08 |
| Average True Range (ATR) | 0.15 | 0.31 |
| MACD | 0.05 | -0.03 |
| Stochastic Oscillator | 78.07 | 24.51 |
Solid Power Inc develops solid-state battery technology and manufacturing processes. Its sulfide-based solid electrolyte material replaces the liquid or gel electrolyte used in traditional lithium-ion battery cells and enables improvement in energy density, battery life and safety performance. The company produces electrolytes on two pilot manufacturing lines using a batch manufacturing process for customer sampling and internal cell development, and manufactures solid-state cells on pre-pilot and pilot cell manufacturing lines. Its cell manufacturing processes are developed around industry-standard lithium-ion battery manufacturing processes and equipment, and it manufactures all cell designs, including cathodes and anodes, using materials sourced from external suppliers.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. It has one reportable segment related to R&D and commercial readiness of its gene therapies.